Initial Data Shows Promising Results for Non-Viral Gene Therapy for Noninfectious Uveitis

Posted on

Eyevensys presented results from the first part of its Phase 1/2 study for noninfectious uveitis. The technology used includes a non-viral gene therapy ocular drug delivery platform that uses a two-part Electrotransfection System that delivers DNA plasmids encoding therapeutic proteins into the ciliary muscle. The eye is then turned into a biofactory and causes the ciliary muscle to produce the therapeutic protein that reaches the back of the eye. The first part of the study tested its lead product, EYS606, a non-viral vector encoding an anti-tumor necrosis factor (alphaTNFα) protein.

The trial included 9 patients (3 cohorts) with late-stage noninfectious uveitis treated with EYS606. Results showed that clinical improvements lasted 6 months after just one treatment for 3 patients. One patient in the lowest dose cohort experienced a >10 ETDRS letter improvement in best corrected visual acuity (BCVA), whereas two patients in the highest dose cohort experienced a significant reduction of macular edema via optical coherence tomography associated with at least +12 ETDRS letters increase in BCVA from baseline.

The Phase 2 clinical study targets patients with active chronic noninfectious uveitis. Eyevensys will also conduct additional testing of different proteins for other ophthalmic diseases, including retinitis pigmentosa, dry age-related macular degeneration (AMD), glaucoma, macular edema associated with wet-AMD, diabetic macular edema, and central retinal vein occlusion.

You can read more here.

Related Articles
Wearable collision warning device helps visually impaired individuals
Jul 22, 2021
Psoriasis linked with significantly higher risk of retinal diseases
Jul 20, 2021
Ranibizumab biosimilar has comparable efficacy, safety profile to reference product in patients with nAMD
Jul 19, 2021